培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析

BACKGROUND AND OBJECTIVE: Whether pemetrexed plus platinum (PP) regimen is superior to gemcitabine plus platinum (GP) regimen for patients with advanced non-small cell lung cancer (NSCLC) is unclear. The aim of this study is to evaluate the efcacy and safety of PP versus GP regimens for patients with NSCLC. METHODS: We searched relevant randomized controlled trials (RCTs) from Pubmed, EMBASE, Cochrane Library, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Chinese Scientifc Journals Full-text Database, and traced the related references to obtain the information that has not been found. We made quality assessment of qualifed RCTs assessed by the exclusion and inclusion criteria and used RevMan 5.0 provided by the Cochrane Collaboration to perform meta-analysis. RESULTS: Four RCTs involving 2, 235 patients were identifed. Tere were no statistical differences between PP and GP regimens in one-year survival rate (OR=1.09, 95%CI: 0.91-1.29), the efciency of disease (OR=1.00, 95%CI: 0.40-2.52), but overall survival (MD=0.26, 95%CI: 0.21-0.30), alopecia (OR=0.51, 95%CI: 0.39-0.66) and hematologic toxicity were signifcantly different. CONCLUSION: The clinical efciency of PP and GP regimens for advanced NSCLC was similar, but the side effects were different. The toxicity of PP regimen has the tendency to be more tolerable.